Literature DB >> 21133887

Differential regulation of β2 -adrenoceptor-mediated inotropic and lusitropic response by PDE3 and PDE4 in failing and non-failing rat cardiac ventricle.

Faraz Afzal1, Jan Magnus Aronsen, Lise Román Moltzau, Ivar Sjaastad, Finn Olav Levy, Tor Skomedal, Jan-Bjørn Osnes, Eirik Qvigstad.   

Abstract

BACKGROUND AND
PURPOSE: β-Adrenoceptors play a major role in regulating myocardial function through cAMP-dependent pathways. Different phosphodiesterases (PDEs) regulate intracellular cAMP-pools and thereby contribute to the compartmentalization of cAMP-dependent effects. We explored the involvement of PDEs in limiting the β(2) adrenoceptor-mediated positive inotropic (PIR) and lusitropic (LR) responses in sham-operated (Sham) and failing rat hearts. EXPERIMENTAL APPROACH: Extensive myocardial infarctions were induced by coronary artery ligation in Wistar rats. Rats developing heart failure were studied 6 weeks after surgery. Contractility was measured in left ventricular strips from failing and Sham hearts. cAMP was quantified by RIA. KEY
RESULTS: In ventricular strips, stimulation of β(2) -adrenoceptors with (-)-adrenaline (300 nM CGP20712A present) exerted a small PIR and LR. In Sham hearts, β(2) -adrenoceptor-mediated as well as β(1) -adrenoceptor-mediated PIR and LR were increased by selective inhibition of either PDE3 (1 µM cilostamide) or PDE4 (10 µM rolipram). In failing rat hearts, PDE3 inhibition enhanced PIR and LR to both β(1) - and β(2) -adrenoceptor stimulation while PDE4 inhibition had no effect on these responses despite a significant increase in cAMP levels. Combined PDE3/4 inhibition further enhanced the PIR and LR of β(2) - and β(1) -adrenoceptor activation both in Sham and failing hearts, compared with PDE3 inhibition alone. PDE4 enzyme activity was reduced in failing hearts. CONCLUSIONS AND IMPLICATIONS: Both PDE3 and PDE4 attenuated β(2) - and β(1) -adrenoceptor-mediated contractile responses in Sham hearts. In failing hearts, these responses are attenuated solely by PDE3 and thus even selective PDE3 inhibitors may provide a profound enhancement of β-adrenoceptor-mediated responses in heart failure.
© 2010 The Authors. Journal compilation © 2010 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21133887      PMCID: PMC3012406          DOI: 10.1111/j.1476-5381.2010.00890.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

Review 1.  Adrenergic and muscarinic receptors in the human heart.

Authors:  O E Brodde; M C Michel
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

Review 2.  Recent advances in cardiac beta(2)-adrenergic signal transduction.

Authors:  R P Xiao; H Cheng; Y Y Zhou; M Kuschel; E G Lakatta
Journal:  Circ Res       Date:  1999-11-26       Impact factor: 17.367

3.  Both beta(2)- and beta(1)-adrenergic receptors mediate hastened relaxation and phosphorylation of phospholamban and troponin I in ventricular myocardium of Fallot infants, consistent with selective coupling of beta(2)-adrenergic receptors to G(s)-protein.

Authors:  P Molenaar; S Bartel; A Cochrane; D Vetter; H Jalali; P Pohlner; K Burrell; P Karczewski; E G Krause; A Kaumann
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

4.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.

Authors:  Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade
Journal:  JAMA       Date:  2002-03-27       Impact factor: 56.272

5.  Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure.

Authors:  Koki Takahashi; Tomohiro Osanai; Takao Nakano; Makoto Wakui; Ken Okumura
Journal:  Heart Vessels       Date:  2002-09       Impact factor: 2.037

6.  The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation.

Authors:  J Backs; A Haunstetter; S H Gerber; J Metz; M M Borst; R H Strasser; W Kübler; M Haass
Journal:  J Mol Cell Cardiol       Date:  2001-03       Impact factor: 5.000

7.  Echocardiographic criteria for detection of postinfarction congestive heart failure in rats.

Authors:  I Sjaastad; O M Sejersted; A Ilebekk; R Bjornerheim
Journal:  J Appl Physiol (1985)       Date:  2000-10

8.  Caveolar localization dictates physiologic signaling of beta 2-adrenoceptors in neonatal cardiac myocytes.

Authors:  Yang Xiang; Vitalyi O Rybin; Susan F Steinberg; Brian Kobilka
Journal:  J Biol Chem       Date:  2002-07-03       Impact factor: 5.157

9.  Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent G(s) signaling during beta2-adrenergic stimulation.

Authors:  Su-Hyun Jo; Veronique Leblais; Ping H Wang; Michael T Crow; Rui-Ping Xiao
Journal:  Circ Res       Date:  2002-07-12       Impact factor: 17.367

10.  Active state in heart muscle. Its delayed onset and modification by inotropic agents.

Authors:  E H Sonnenblick
Journal:  J Gen Physiol       Date:  1967-01       Impact factor: 4.086

View more
  9 in total

1.  β-Adrenergic receptor stimulation increases surface NKCC2 expression in rat thick ascending limbs in a process inhibited by phosphodiesterase 4.

Authors:  Mohammed Z Haque; Paulo S Caceres; Pablo A Ortiz
Journal:  Am J Physiol Renal Physiol       Date:  2012-08-29

2.  Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.

Authors:  O Orstavik; S H Ata; J Riise; C P Dahl; G Ø Andersen; F O Levy; T Skomedal; J-B Osnes; E Qvigstad
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

3.  Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium.

Authors:  Lise Román Moltzau; Silja Meier; Jan Magnus Aronsen; Faraz Afzal; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Eirik Qvigstad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-01-15       Impact factor: 3.000

4.  Non-classical regulation of β1- and β 2-adrenoceptor-mediated inotropic responses in rat heart ventricle by the G protein Gi.

Authors:  Caroline Bull Melsom; Rizwan Iqbal Hussain; Øivind Ørstavik; Jan Magnus Aronsen; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Kurt Allen Krobert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-09-13       Impact factor: 3.000

5.  Cardiac PDEs and crosstalk between cAMP and cGMP signalling pathways in the regulation of contractility.

Authors:  Finn Olav Levy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-05-07       Impact factor: 3.000

6.  Agents increasing cyclic GMP amplify 5-HT4-elicited positive inotropic response in failing rat cardiac ventricle.

Authors:  Faraz Afzal; Eirik Qvigstad; Jan Magnus Aronsen; Lise Román Moltzau; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-08       Impact factor: 3.000

7.  The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium.

Authors:  Øivind Ørstavik; Ornella Manfra; Kjetil Wessel Andressen; Geir Øystein Andersen; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Kurt Allen Krobert
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

Review 8.  Phosphodiesterases and Compartmentation of cAMP and cGMP Signaling in Regulation of Cardiac Contractility in Normal and Failing Hearts.

Authors:  Gaia Calamera; Lise Román Moltzau; Finn Olav Levy; Kjetil Wessel Andressen
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

9.  Compartmentation of β2 -adrenoceptor stimulated cAMP responses by phosphodiesterase types 2 and 3 in cardiac ventricular myocytes.

Authors:  Michael W Rudokas; John P Post; Alejandra Sataray-Rodriguez; Rinzhin T Sherpa; Karni S Moshal; Shailesh R Agarwal; Robert D Harvey
Journal:  Br J Pharmacol       Date:  2021-02-20       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.